Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab and Zeprumetostat in Follicular Lymphoma
NCT07555470Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Apr 2026
- Primary completion
- Dec 2029
- Modality
- Small Molecules, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of mosunetuzumab, zeprumetostat in follicular lymphoma (FL), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Apr 2026; status: recruiting.
02
Drugs
mosunetuzumabzeprumetostat
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT07555470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07555470.